PSMA hybrid imaging in prostate cancer – current applications and perspectives
RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren · 01.11.2023 · 195 (11) · 1001-1008
DOI: 10.1055/a-2088-9543 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren, erschienen am 01.11.2023. Verfasst von Daniel Koehler und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Prostatic Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben.
Abstract (Originalsprache)
Background
Prostate cancer (PCa) is the most common malignancy in men and the second most common tumor-associated cause of death in the male population in Germany. Prostate-specific membrane antigen (PSMA)-targeted hybrid imaging using positron emission tomography (PET) in combination with CT or MRI represents a comparably new method that gained increasing importance in the diagnostic process of PCa in recent years.
Method
Current applications of PSMA hybrid imaging were summarized according to the German and European guidelines on PCa. New developments were elaborated based on a literature review of PubMed conducted in 10/22.
Results
PSMA-PET/CT demonstrated higher detection rates for metastases in high-risk PCa and recurrent PCa after primary therapy than established imaging methods (CT, MRI, and bone scan). Despite promising results from prospective trials in both scenarios and substantial influence on clinical decision making, data regarding the influence of PSMA-PET on PCa-specific and overall survival are still lacking. Hence, PSMA PET/CT is recommended with a “weak” strength rating in most situations. However, its importance in new treatment options like metastasis-directed therapy or PSMA-radioligand therapy expands the scope of PSMA-PET in the clinical routine.
Conclusion
PSMA-targeting hybrid imaging represents the most sensitive diagnostic test in several stages of PCa and allows the development of new treatment strategies. Prospective studies are needed to evaluate the influence of PSMA-PET on patient survival. Key Points Citation Format
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Department of Nuclear Medicine, University Hospital Essen, Germany.
ORCID-Profile: Daniel Koehler, Christoph Berliner, Markus Sauer
Zitieren
APA
Koehler, D., Berliner, C., Shenas, F., Karimzadeh, A., Apostolova, I., Klutmann, S., Adam, G., & Sauer, M. (2023). PSMA hybrid imaging in prostate cancer – current applications and perspectives. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren, 195(11), 1001-1008. https://doi.org/10.1055/a-2088-9543
Vancouver
Koehler D, Berliner C, Shenas F, Karimzadeh A, Apostolova I, Klutmann S, et al. PSMA hybrid imaging in prostate cancer – current applications and perspectives. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren. 2023;195(11):1001-1008. doi:10.1055/a-2088-9543
BibTeX
@article{Koehler2023,
author = {Koehler, Daniel and Berliner, Christoph and Shenas, Farzad and Karimzadeh, Amir and Apostolova, Ivayla and Klutmann, Susanne and Adam, Gerhard and Sauer, Markus},
title = {PSMA hybrid imaging in prostate cancer – current applications and perspectives},
journal = {RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren},
year = {2023},
volume = {195},
number = {11},
pages = {1001--1008},
doi = {10.1055/a-2088-9543}
}
EUVIMED